Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05192122

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

Led by University of Illinois at Chicago · Updated on 2025-12-18

50

Participants Needed

1

Research Sites

365 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

CONDITIONS

Official Title

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • ECOG Performance Status equal to or less than 2 within 30 days prior to registration
  • Revised International Staging System (R-ISS) stage I, 2, or 3
  • Diagnosis of Multiple Myeloma as defined by International Myeloma Working Group (IMWG)
  • Completed at least 2 years of post-autologous stem cell transplant (ASCT) maintenance therapy
  • Maintenance therapy includes any anti-myeloma treatment started after ASCT to prevent recurrence (e.g., lenalidomide, bortezomib, RVD)
  • Disease response is very good partial response (VGPR) or complete response (CR) at enrollment by IMWG criteria
  • Ability to understand and sign informed consent or have a legally authorized representative to do so
Not Eligible

You will not qualify if you...

  • Diagnosis of plasma cell leukemia, AL amyloidosis, or POEMS syndrome
  • Prior organ transplant or conditions requiring immunosuppressive therapy
  • Previous allogeneic hematopoietic cell transplant
  • Treatment with any investigational drug within 30 days before enrollment
  • Unable to sign informed consent or lack of legally authorized representative

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Illinois Cancer Center

Chicago, Illinois, United States, 60612

Actively Recruiting

Loading map...

Research Team

K

Karen Sweiss, PharmD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here